COMMUNIQUÉS West-GlobeNewswire
-
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
10/03/2026 -
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026 -
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
10/03/2026 -
Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000
10/03/2026 -
Nominations Now Open for PerfectServe’s Sixth Annual Nurses of Note Awards Program
10/03/2026 -
Spectral AI Schedules 2025 Fourth Quarter and Full Year Financial Results and Conference Call
10/03/2026 -
UPDATED – Moving from Pledge to Production, Clover Health is Now Live on Kno2, Participating in Recently Announced Federal Interoperability Initiatives
10/03/2026 -
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
10/03/2026 -
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
10/03/2026 -
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
10/03/2026 -
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
10/03/2026 -
Experts at Park Mental Health Announce New Therapeutic Approach: Highlighting the Role of Community Support in Recovery
10/03/2026 -
Imprivata Introduces Agentic Identity Management to Secure and Govern AI Agents in Healthcare
10/03/2026 -
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
10/03/2026 -
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
10/03/2026 -
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026 -
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
10/03/2026 -
Shoreline Recovery Center Experts Announce New Therapeutic Approach In Addiction Recovery
10/03/2026 -
Roche Annual General Meeting 2026
10/03/2026
Pages